Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
RedHill Biopharma ( (RDHL) ) has issued an update.
On October 20, 2025, RedHill Biopharma amended its Any Market Purchase Agreement with Alumni Capital LP, increasing the ownership limit for Forward Purchase Notices from 4.99% to 9.99%. This amendment allows RedHill greater flexibility in capital raising through the sale of American Depositary Shares, potentially impacting its financial strategy and market positioning.
The most recent analyst rating on (RDHL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
Spark’s Take on RDHL Stock
According to Spark, TipRanks’ AI Analyst, RDHL is a Neutral.
RedHill Biopharma’s overall stock score is primarily impacted by its challenging financial performance, characterized by consistent losses and high leverage. The technical analysis indicates weak momentum, and the lack of valuation metrics further underscores financial instability. These factors collectively suggest a high-risk investment profile.
To see Spark’s full report on RDHL stock, click here.
More about RedHill Biopharma
RedHill Biopharma is a biopharmaceutical company based in Tel Aviv, Israel, focusing on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases and cancer. The company is engaged in various stages of clinical development and aims to address unmet medical needs in these areas.
Average Trading Volume: 1,390,185
Technical Sentiment Signal: Sell
Current Market Cap: $5.76M
See more insights into RDHL stock on TipRanks’ Stock Analysis page.